JAK2 Mutations and JAK Inhibitors in the Management of Myeloproliferative Neoplasms
The Philadelphia chromosomeâ€“negative myeloproliferative neoplasms (MPNs) are clonal disorders characterized by common mutations, but with distinct clinical features, treatment considerations, and prognostic outlooks.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512